Cialis vs Alprostadil (Caverject/MUSE): Cost and Access Head-to-Head

How Pricing Compares in 2026

Generic tadalafil is one of the least expensive branded-to-generic conversions in urology. Since Cialis lost patent protection in September 2018, retail cash prices have dropped from roughly $400 for 30 tablets of brand Cialis 20 mg to as low as $9 to $60 for the same quantity of generic tadalafil, depending on pharmacy and dose [3]. GoodRx and similar discount platforms routinely list 30 tablets of tadalafil 5 mg (daily dosing) below $30.

Alprostadil never experienced the same pricing collapse. Brand Caverject Impulse (20 mcg, single-use) carries a typical cash price of $50 to $75 per injection at chain pharmacies. MUSE suppositories (500 mcg or 1 to 000 mcg) range from $25 to $60 per unit. A man using alprostadil twice weekly spends $200 to $600 per month without coverage, compared to $10 to $60 per month for daily or as-needed tadalafil.

The arithmetic is stark. Even at the highest generic tadalafil price point, a full month of daily 5 mg dosing costs less than two Caverject injections at the lowest alprostadil price point. That gap widens for men with commercial insurance: tadalafil sits on most formularies at Tier 1 or Tier 2, while alprostadil formulations often land on Tier 3 (preferred brand) or require a prior authorization documenting PDE5 inhibitor failure [4].

Insurance and Formulary Placement

Tadalafil's formulary position improved after generic entry. As of 2025, major pharmacy benefit managers (Express Scripts, CVS Caremark, OptumRx) list generic tadalafil on preferred tiers with copays between $5 and $25 for a 30-day supply. Some plans still impose quantity limits (typically 6 to 12 tablets per month for as-needed dosing, or 30 tablets per month for daily 5 mg) [5].

Alprostadil coverage is less predictable. Medicare Part D plans may cover Caverject or MUSE under the specialty tier with 25% to 33% coinsurance after the deductible. Step therapy requirements are common: the plan requires documented failure of at least one PDE5 inhibitor before approving alprostadil. Prior authorization paperwork adds 3 to 14 days of delay [6].

The VA formulary provides an instructive contrast. Tadalafil is listed as a formulary agent with no prior authorization at most VA medical centers. Alprostadil injection is non-formulary at many VA sites, requiring a non-formulary request with clinical justification. For veterans with service-connected ED, this distinction can determine whether treatment begins in one visit or three.

"Coverage for erectile dysfunction therapies varies enormously across payers, but the consistent pattern is that oral PDE5 inhibitors face fewer administrative barriers than injectable or intraurethral alprostadil," notes the American Urological Association's 2018 guideline on ED management [7].

Clinical Efficacy: What the Trials Show

Tadalafil earned FDA approval based on multiple randomized controlled trials. Brock et al. (2002, N=1,112) demonstrated that tadalafil 20 mg produced successful intercourse attempts in 73% of tries versus 32% for placebo (P<0.001) [1]. The drug's 36-hour half-life allowed a wider dosing window than sildenafil or vardenafil, and a subsequent trial program established that daily tadalafil 5 mg provides continuous erectile support while also treating lower urinary tract symptoms from benign prostatic hyperplasia [8].

Alprostadil operates through a completely different mechanism. Rather than inhibiting PDE5 to amplify the nitric oxide/cGMP pathway, alprostadil is a synthetic prostaglandin E1 that directly relaxes cavernosal smooth muscle. Linet and Ogrinc (1996, N=296) reported that intracavernosal alprostadil produced erections sufficient for intercourse in approximately 70% of men, including a subset who had not responded to oral agents [2]. This remains the drug's primary clinical advantage: it works when pills do not.

No large, head-to-head randomized trial has directly compared tadalafil to alprostadil. The evidence base consists of separate key programs in overlapping but not identical patient populations. Tadalafil trials enrolled men with mild-to-severe ED across a range of etiologies. Alprostadil trials, particularly Linet et al., included a higher proportion of men with vascular and neurogenic ED who had failed other therapies.

A crossover preference study by Shabsigh et al. (2000, N=126) compared intracavernosal alprostadil to oral sildenafil (not tadalafil) and found that 68% of men preferred the oral agent despite similar erectile rigidity scores [9]. Patient convenience, not efficacy, drove the preference gap.

Route of Administration and Real-World Convenience

Tadalafil is a pill. That simplicity shapes everything downstream: prescribing patterns, patient adherence, telehealth accessibility, and partner acceptance. A man takes 5 mg daily with breakfast or 10 to 20 mg as needed before sexual activity. No refrigeration. No injection training. No sterile technique.

Alprostadil demands more. Caverject requires the patient to self-inject 5 to 40 mcg into the lateral corpus cavernosum using a 27- to 30-gauge needle. Dose titration typically starts in-office under clinician supervision, a process that may take one to three visits to identify the optimal dose that produces an erection lasting 30 to 60 minutes without priapism [10]. MUSE reduces the needle burden by delivering alprostadil as a urethral suppository via a small applicator, but absorption is less predictable, and efficacy rates run lower than injection (43% vs. 70% in comparative analyses) [11].

Real-world adherence data reflect this divide. A retrospective claims analysis published in the Journal of Sexual Medicine found that 12-month persistence with oral PDE5 inhibitors was 56%, compared to 32% for intracavernosal injection therapy [12]. The primary reasons for discontinuation of alprostadil were injection anxiety, penile pain (reported in 30% to 50% of patients in clinical trials), and the inconvenience of preparation.

Access Through Telehealth and Online Pharmacies

The telehealth expansion since 2020 dramatically favored oral ED medications. Platforms prescribing tadalafil via asynchronous consultation and mail-order pharmacy have proliferated. A patient can complete an intake questionnaire, receive a prescription within hours, and have generic tadalafil delivered to his door for under $1 per dose.

Alprostadil fits poorly into this model. Most state medical boards and the AUA recommend that initial alprostadil dosing occur in-office to monitor for priapism (sustained erection lasting more than 4 hours, reported in 1% to 4% of patients) and to ensure proper injection technique [7]. After a patient demonstrates competence, refill prescriptions can be managed remotely, but the barrier to initiation remains an in-person visit.

MUSE has slightly better telehealth compatibility since it avoids needles, but the lower efficacy and the recommendation for in-office first-dose observation limit its adoption in pure-telehealth workflows.

When Alprostadil Makes Clinical Sense Despite the Cost

Price and convenience favor tadalafil for the majority of men with ED. But alprostadil fills a specific clinical niche that oral agents cannot. The AUA guideline identifies intracavernosal injection as a second-line therapy for men who fail, cannot tolerate, or have contraindications to PDE5 inhibitors [7].

Specific populations where alprostadil may be preferred include:

Men taking nitrates for coronary artery disease cannot safely use any PDE5 inhibitor due to the risk of severe hypotension. Alprostadil carries no such contraindication.

Post-radical prostatectomy patients with complete cavernosal nerve disruption may not generate enough endogenous nitric oxide for PDE5 inhibitors to amplify. Alprostadil bypasses this requirement by directly inducing smooth muscle relaxation. Montorsi et al. (1997) demonstrated that early intracavernosal alprostadil after prostatectomy improved long-term erectile recovery rates [13].

Men with severe vasculogenic ED and diabetes who fail maximum-dose tadalafil (20 mg) plus vacuum erection devices often respond to intracavernosal alprostadil at doses of 20 to 40 mcg.

"For patients who do not respond to PDE5 inhibitors or in whom they are contraindicated, intracavernosal alprostadil remains the most effective non-surgical treatment for erectile dysfunction," states the 2018 AUA/SMSNA guideline on ED [7].

Switching Between Tadalafil and Alprostadil

Switching from tadalafil to alprostadil does not require a washout period. Tadalafil's 17.5-hour half-life means it clears within 3 to 4 days, but there is no pharmacological interaction between the two drugs. A clinician may initiate alprostadil dose titration while the patient discontinues tadalafil.

The reverse switch (alprostadil to tadalafil) is straightforward. The clinician stops alprostadil injections and prescribes tadalafil 5 mg daily or 10 mg as needed. No overlap period or bridging protocol is necessary.

Combination therapy (daily tadalafil plus as-needed low-dose intracavernosal alprostadil) has been described in case series but lacks strong RCT evidence. McMahon et al. (2006) reported improved IIEF scores with combination therapy in men with severe ED refractory to monotherapy [14]. This approach increases both cost and complexity and should be reserved for specialist-managed cases.

Compounding Pharmacy Options and 503B Outsourcing

Some men access alprostadil through compounding pharmacies at lower cost. A compounded intracavernosal "trimix" (alprostadil + papaverine + phentolamine) vial supplying 10 to 20 doses can cost $80 to $150 total, bringing the per-dose cost to $4 to $15. This makes compounded alprostadil-based injections more price-competitive with generic tadalafil than brand Caverject [15].

Compounded trimix is not FDA-approved. The FDA regulates compounding pharmacies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Patients using compounded injectables should confirm that their pharmacy holds current state licensure and, ideally, 503B outsourcing facility registration with the FDA [16]. Storage requirements (refrigeration, protection from light) are stricter for compounded formulations than for commercially manufactured alprostadil.

Generic tadalafil has no meaningful compounding equivalent since the oral tablet is already inexpensive and widely available.

Side Effect Profiles and Cost of Managing Adverse Events

Tadalafil's most common adverse effects are headache (14.5%), dyspepsia (12.3%), back pain (6.5%), and nasal congestion (4.3%) [1]. These are generally mild and do not require medical treatment, adding no cost burden.

Alprostadil's side effect profile carries direct cost implications. Penile pain occurs in 37% of injection users and 24% to 33% of MUSE users in clinical trials [2][11]. While most pain resolves without treatment, some men require topical lidocaine or dose adjustments that mean additional office visits. Priapism, though uncommon (1% to 4%), constitutes a urological emergency requiring ED department intervention and possible aspiration/irrigation with phenylephrine, a visit that can cost $1,500 to $5,000 out of pocket [17]. Penile fibrosis or Peyronie's-like nodules develop in 2% to 9% of long-term injection users, potentially requiring further treatment [10].

These downstream costs are rarely factored into head-to-head pricing comparisons but matter for total cost of care.

The Bottom Line for Prescribers and Patients

For most men with ED, generic tadalafil is the rational starting point on both clinical and economic grounds. It is effective, inexpensive, orally administered, widely covered by insurance, and accessible through telehealth. Alprostadil (Caverject injection or MUSE suppository) costs 10 to 50 times more per dose in brand form, requires in-office titration, and carries a higher side-effect management burden. Its clinical value is concentrated in the population that genuinely fails oral PDE5 inhibitors or carries contraindications like concurrent nitrate therapy. For that subgroup, the AUA recommends intracavernosal alprostadil as the most effective non-surgical second-line option [7]. Compounded trimix narrows the cost gap substantially and may be the most practical path for long-term injection users who confirm their pharmacy's regulatory standing with their prescribing clinician.